NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs

Author(s): M. Munoz, R. Covenas

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 12 , Issue 7 , 2012

Become EABM
Become Reviewer
Call for Editor


After binding to the neurokinin-1 (NK-1) receptor, substance P (SP) induces tumor cell proliferation, angiogenesis, and the migration of tumor cells for invasion and metastasis. After binding to NK-1 receptors, NK-1 receptor antagonists inhibit tumor cell proliferation, angiogenesis and the migration of tumor cells. These antagonists are broad-spectrum antitumor drugs. In addition, in the host they display beneficial effects: anxiolytic, antiemetic, neuroprotector, nephroprotector, hepatoprotector, antiinflammatory and analgesic. In combination therapy with classic cytostatics, NK-1 receptor antagonists have synergic effects and minimize the side-effects of these classic drugs. Thus, NK-1 receptor antagonists could offer a new and promising generation of anticancer drugs.

Keywords: Substance P, neoangiogenesis, metastasis, tumor cells, apoptosis, preprotachykinin A, in situ, malignant melanomas, gastric motility, SP-immunoreactivity, NK-1 receptors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 10 May, 2012
Page: [593 - 599]
Pages: 7
DOI: 10.2174/138955712800626692
Price: $65

Article Metrics

PDF: 24